Royalty Pharma
Quarterly Financials
| Values in thousands | 2024-06-30 | 2024-03-31 | 2023-12-31 | 2023-09-30 |
|---|---|---|---|---|
Revenue | $537,267 | $567,978 | $596,000 | $536,313 |
Gross Profit | 531,267 | -15,622 | 519,487 | 259,176 |
EBITDA | 269,630 | -73,774 | 613,000 | 167,949 |
EBIT | -290,370 | -803,548 | 611,582 | 166,531 |
Net Income | 102,004 | 4,778 | 494,340 | 72,114 |
Net Change In Cash | 537,267 | 567,978 | 596,000 | 536,313 |
Free Cash Flow | -84,476 | 583,519 | -224,954 | 573,520 |
Cash | 1,764,644 | 843,000 | 477,010 | 936,448 |
Basic Shares | 596,912 | 597,479 | 446,568 | 601,138 |
Annual Financials
| Values in thousands | 2023-12-31 | 2022-12-31 | 2021-12-31 | 2020-12-31 |
|---|---|---|---|---|
Revenue | $2,354,554 | $2,237,215 | $2,289,463 | $2,122,000 |
Gross Profit | 1,793,898 | 2,231,545 | 2,266,467 | 2,033,889 |
EBITDA | 1,492,150 | 983,169 | 1,482,078 | 1,882,000 |
EBIT | 1,486,480 | 977,499 | 1,459,082 | 1,858,942 |
Net Income | 1,134,834 | 42,832 | 478,754 | 495,198 |
Net Change In Cash | 2,354,554 | 2,237,215 | 2,289,463 | 2,122,000 |
Cost of Revenue | 169,703 | 532,368 | 762,481 | |
Free Cash Flow | 916,162 | 4,185,132 | 2,018,059 | 4,231,629 |
Cash | 477,010 | 1,710,751 | 1,541,048 | 1,009,000 |
Basic Shares | 602,900 | 437,972 | 414,802 | 375,455 |
Earnings Calls
| Quarter | EPS |
|---|---|
2024-06-30 | $0.96 |
2024-03-31 | $0.98 |
2023-12-31 | $1.15 |
2023-09-30 | $0.79 |
